阿卡西作为一种天然的心血管治疗药物:机制和临床前证据
Zihe Zhou1,2, Tao Li3, Helin Qin1
1Department of Cardiology, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, China.
Frontiers in pharmacology
|April 21, 2025
概括
作为一种天然的黄类化合物,阿卡西通过减少氧化应激和炎症来保护心血管疾病 (CVD). 需要进一步的研究来确认其临床疗效和CVD治疗的生物可用性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
- 自然产品 化学 化学
背景情况:
- 心血管疾病 (CVD) 是全球主要的死亡原因,由于人口老龄化,发病率增加.
- 阿卡西是一种植物衍生的黄类化合物,具有多种药理性质,包括抗氧化和抗炎作用.
- 新兴的临床前证据表明,阿卡素具有显著的心血管保护潜力.
研究的目的:
- 系统地审查阿卡的心血管保护作用.
- 阐明阿卡塞丁心脏保护的潜在分子机制.
- 评估阿卡塞丁作为治疗心血管疾病的新疗剂的潜力.
主要方法:
- 关于阿卡和心血管疾病的临床前研究的综合文献综述.
- 分析了研究调查阿卡对各种心血管疾病模型 (心律失常,缺血/再输,动脉样硬化等) 的影响的研究. ) 的情况.
- 检查详细研究的分子途径和细胞机制,涉及到阿卡塞丁的心脏保护作用.
主要成果:
- 阿卡西显示出对一系列心血管疾病的保护作用,包括心律失常,心脏缺血/再输损伤,动脉样硬化,心肌缩,纤维化,药物诱导的心脏毒性,糖尿病心肌病,高血压和心脏衰老.
- 关键机制包括抑制氧化应激,炎症,心肌细胞亡和内皮损伤.
- 阿卡西调节线粒体自,脂质代谢,并调节PI3K/Akt/mTOR,Sirt1/AMPK/PGC-1α,TGF-β1/Smad3和Akt/eNOS等关键信号通路.
结论:
- 阿卡西通过多种分子机制表现出广泛的心血管保护作用.
- 阿卡是新型心血管治疗的有希望的候选者.
- 进一步的临床研究至关重要,以验证疗效和改善治疗应用的生物可用性.
更多相关视频
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
95
07:40Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
1.0K
相关概念视频
01:16Antianginal Drugs: Nitrates and β-Blockers
437
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
437
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
305
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
305
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
379
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
379
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
385
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
385
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
99
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
99
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
1.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
1.9K